Loading…

Boosting NAD+ with a small molecule that activates NAMPT

Pharmacological strategies that boost intracellular NAD + are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD + precursor in mammalian cells....

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2019-07, Vol.10 (1), p.3241-12, Article 3241
Main Authors: Gardell, Stephen J., Hopf, Meghan, Khan, Asima, Dispagna, Mauro, Hampton Sessions, E., Falter, Rebecca, Kapoor, Nidhi, Brooks, Jeanne, Culver, Jeffrey, Petucci, Chris, Ma, Chen-Ting, Cohen, Steven E., Tanaka, Jun, Burgos, Emmanuel S., Hirschi, Jennifer S., Smith, Steven R., Sergienko, Eduard, Pinkerton, Anthony B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacological strategies that boost intracellular NAD + are highly coveted for their therapeutic potential. One approach is activation of nicotinamide phosphoribosyltransferase (NAMPT) to increase production of nicotinamide mononucleotide (NMN), the predominant NAD + precursor in mammalian cells. A high-throughput screen for NAMPT activators and hit-to-lead campaign yielded SBI-797812, a compound that is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 shifts the NAMPT reaction equilibrium towards NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD + . These effects of SBI-797812 turn NAMPT into a “super catalyst” that more efficiently generates NMN. Treatment of cultured cells with SBI-797812 increases intracellular NMN and NAD + . Dosing of mice with SBI-797812 elevates liver NAD + . Small molecule NAMPT activators such as SBI-797812 are a pioneering approach to raise intracellular NAD + and realize its associated salutary effects. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate determining step for NAD + synthesis and is of interest as a drug target. Here the authors identify and characterize a small molecule NAMPT activator SBI-797812, elucidate its mode of action and show that it increases intracellular NMN and NAD + levels in cultured cells and elevates liver NAD + in mice.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-019-11078-z